BCAX (Bicara Therapeutics) Book Value per Share: $7.84 (As of Mar. 2026)

What is Bicara Therapeutics Book Value per Share?

Bicara Therapeutics BCAX -2.12% 12 Book Value per Share is $7.84 as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Bicara Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $7.84.

During the past 12 months, Bicara Therapeutics's average Book Value Per Share Growth Rate was -21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Bicara Therapeutics's current price is $29.04. Its book value per share for the quarter that ended in Mar. 2026 was $7.84. Hence, today's PB Ratio of Bicara Therapeutics is 3.70.

During the past 4 years, the highest P/B Ratio of Bicara Therapeutics was 3.80. The lowest was 0.00. And the median was 0.00.

Bicara Therapeutics (NAS:BCAX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Bicara Therapeutics Book Value per Share Related Terms

Bicara Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Book Value per Share Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Dec25

Book Value per Share

-1.91

-2.87

9.04

7.09

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Book Value per Share	Get a 7-Day Free Trial							8.42	7.98	7.38	7.09	7.84

BCAX vs ZYME, SRPT, INVA: Book Value per Share Comparison

For the Biotechnology subindustry, Bicara Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's PB Ratio falls into.

Save Embed

12GF Score

Bicara Therapeutics Inc BCAX

Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bicara Therapeutics Book Value per Share Calculation

Bicara Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(401.45	-	0.00)	/	56.60
	=	7.09

Bicara Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(513.96	-	0.00)	/	65.55
	=	7.84

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →

What does a Book Value per Share of $7.84 mean?

Bicara Therapeutics (BCAX) has a Book Value per Share of $7.84 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bicara Therapeutics and its competitors.

Is Bicara Therapeutics' Book Value per Share too high?

Bicara Therapeutics' current Book Value per Share is $7.84. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Bicara Therapeutics' Book Value per Share compare to ZYME and SRPT?

Bicara Therapeutics' Book Value per Share of $7.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Book Value per Share for a Biotechnology company?

A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Book Value per Share mean?

A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Book Value per Share is $7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bicara Therapeutics stock overvalued right now?

Bicara Therapeutics (BCAX) has a current Book Value per Share of $7.84. The current Book Value per Share is $7.84. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Book Value per Share calculated?

Book Value per Share is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Book Value per Share is $7.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ZYME SRPT INVA TSHA VIR ANAB ABSI URGN SEPN FTRE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

12GF Score

Get the complete analysis for BCAX

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.04

Price

View BCAX Analysis

See Book Value per Share data for all stocks →